Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

CLINICAL AND EXPERIMENTAL ALLERGY is a premier peer-reviewed journal dedicated to advancing the scientific understanding of allergy and immunology. Published by Wiley in the United Kingdom, this esteemed journal maintains a significant impact factor, reflecting its high standards and influential research contributions. With an impressive history since its inception in 1971, the journal is poised to continue leading the discourse in the field until at least 2024. It is ranked in the Q2 quartile for both Immunology and Allergy categories, further highlighting its reputable standing within the academic community. The journal's Scopus rankings showcase its academic relevance, securing the 49th and 51st positions in the Medicine and Immunology categories, respectively. Researchers, professionals, and students will find vital insights and contemporary research trends within its pages, making it an essential resource for those invested in understanding and addressing allergic diseases and disorders.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

Allergy Asthma & Immunology Research, published by the Korean Academy of Asthma Allergy & Clinical Immunology, is a leading journal dedicated to advancing the fields of immunology, allergy, and respiratory medicine. With an ISSN of 2092-7355 and an E-ISSN of 2092-7363, this esteemed publication has been a cornerstone for researchers and practitioners since its inception in 2009 and continues to disseminate critical findings through till 2024. The journal is ranked in the Q3 category in Immunology and the Q2 category in Immunology and Allergy as well as Pulmonary and Respiratory Medicine, illustrating its impact in these vital fields. With a solid Scopus ranking in multiple sub-disciplines, the journal not only contributes to the scientific discourse but also promotes innovative research and clinical practices. Although currently operating without an open access model, the journal remains highly regarded for its thorough peer-review process and commitment to academic excellence, making it an essential resource for professionals, researchers, and students passionate about advancing knowledge in allergy, asthma, and immunology.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.